Evidence map›Paper›PMID 39563372›Full record

ArticleBMC biology2024

Motif-guided identification of KRAS-interacting proteins.

Sanan Wu, Xiaoyang Gao, Di Wu, Lu Liu, Han Yao, Xiangjun Meng, Xianglei Zhang, Fang Bai

Abstract read
In one paragraph

Article in BMC biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sanan WuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Xiaoyang GaoShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Di WuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Lu LiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Han YaoDepartment of Gastroenterology of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiangjun MengDepartment of Gastroenterology of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. meng_xiangjun@yahoo.com.
Xianglei ZhangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China. zhangxl6@shanghaitech.edu.cn.
Fang BaiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China. baifang@shanghaitech.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor decades, KRAS has always been a huge challenge to the field of drug discovery for its significance in cancer progression as well as its difficulties in being targeted as an "undruggable" protein. KRAS regulates downstream signaling pathways through protein-protein interactions, whereas many interaction partners of KRAS remain unknown.

resultsWe developed a workflow to computationally predict and experimentally validate the potential KRAS-interacting proteins based on the interaction mode of KRAS and its known binding partners. We extracted 17 KRAS-interacting motifs from all experimentally determined KRAS-containing protein complexes as queries to identify proteins containing fragments structurally similar to the queries in the human protein structure database using our in-house protein-protein interaction prediction method, PPI-Miner. Finally, out of the 78 predicted potential interacting proteins of KRAS, 10 were selected for experimental validation, including BRAF, a previously reported interacting protein, which served as the positive control in our validation experiments. Additionally, a known peptide that binds to KRAS, KRpep-2d, was also used as a positive control. The predicted interacting motifs of these 10 proteins were synthesized to perform biolayer interferometry assays, with 4 out of 10 exhibiting binding affinities to KRAS, and the strongest, GRB10, was selected for further validation. Additionally, the interaction between GRB10 (RA-PH domain) and KRAS was confirmed via immunofluorescence and co-immunoprecipitation.

conclusionsThese results demonstrate the effectiveness of our workflow in predicting potential interacting proteins for KRAS and deepen the understanding of KRAS-driven tumor mechanisms and the development of therapeutic strategies.

Indexed as

Proto-Oncogene Proteins p21(ras)Amino Acid MotifsHumansProtein BindingKRAS protein, humanProto-Oncogene Proteins p21(ras)KRASMotif-guided searchingProtein–protein interaction

Identifiers

PMID39563372
PMCPMC11575137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.